Self-testing and self-treating are becoming bigger trends in medicine, and now, you can conduct part of your treatment at home by yourself if you have Alzheimer’s disease.

On Aug. 30, the U.S. Food and Drug Administration (FDA) approved the first at-home treatment for Alzheimer’s. Lecanemab, sold under the brand name Leqembi—which the FDA approved in 2023 as the first medication to treat the memory disorder—is now available in a self-injecting pen, Leqembi Iqlik. People can use the pen to give themselves weekly maintenance doses of the drug. Lecanemab, made by Eisai and Biogen, was originally approved as an IV infusion that took about an hour and required patients to visit infusion clinics once a month. The at-home version is approved as a maintenance therapy that people can give them

See Full Page